Akeso, Inc. (HKG:9926)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
132.70
-3.00 (-2.21%)
Sep 26, 2025, 4:08 PM HKT
-2.21%
Market Cap122.24B
Revenue (ttm)2.75B
Net Income (ttm)-927.04M
Shares Out921.14M
EPS (ttm)-1.06
PE Ration/a
Forward PE392.96
Dividendn/a
Ex-Dividend Daten/a
Volume6,672,164
Average Volume15,077,267
Open132.10
Previous Close135.70
Day's Range128.50 - 135.30
52-Week Range54.00 - 179.00
Beta0.46
RSI42.95
Earnings DateNov 26, 2025

About Akeso

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat my... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 3,035
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9926
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

Akeso's Ligufalimab Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia

(RTTNews) - Akeso Inc. (AKESF, 9926.HK) announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting CD47, ligufalimab (AK117), has been granted Orphan Drug Designation ...

12 days ago - Nasdaq

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Summit Therapeutics Inc . (NASDAQ: SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cance...

20 days ago - Benzinga

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc (NASDAQ: SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small ...

4 weeks ago - Benzinga

Akeso (9926.HK) Soars on Positive Lung Cancer Drug Trial Results

Akeso (9926.HK) Soars on Positive Lung Cancer Drug Trial Results

4 weeks ago - GuruFocus

Chinese biotech firm Akeso sinks after US partner’s cancer-drug setback

Chinese biotech firm Akeso, whose cancer drug has been hailed as breakthrough for the nation’s pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for a quick ...

4 months ago - South China Morning Post

Why Is Summit Therapeutics Stock Trading Higher On Monday?

Summit Therapeutics Inc. (NASDAQ: SMMT) on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a secon...

5 months ago - Benzinga

China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.

5 months ago - South China Morning Post

What's Going On With Summit Therapeutics Stock On Friday?

Summit Therapeutics Inc (NASDAQ: SMMT) stock is trading lower on Friday. On Thursday, Summit Therapeutics’ partner Akeso Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-...

5 months ago - Benzinga

Why Is Summit Therapeutics Stock Soaring On Wednesday?

Summit Therapeutics Inc.'s (NASDAQ: SMMT) partner, Akeso, Inc. , released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with ...

5 months ago - Benzinga

Akeso (9926) Poised for Growth Despite Current Undervaluation

Akeso (9926) Poised for Growth Despite Current Undervaluation

5 months ago - GuruFocus

Why This Chinese Biotech Could Be Pharma's DeepSeek

The drugmaker's shares rallied after the release of its strong annual report, up by a cumulative 18% over the next three trading days Key Takeaways: Akeso's drug sales rose 25% last year to just above...

6 months ago - Benzinga

Akeso reports FY results

6 months ago - Seeking Alpha

Chinese drug maker Akeso hailed as biotech's 'DeepSeek moment' amid US competition

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed as the "DeepSeek moment" for China's drug industry, as biotech emerges as a...

7 months ago - Yahoo

Chinese drug maker Akeso hailed as biotech’s ‘DeepSeek moment’ amid US competition

Akeso’s immunotherapy drug allowed half of its patients to go 11.1 months without their condition worsening.

7 months ago - South China Morning Post

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential

Goldman Sachs has upgraded BioNTech SE (NASDAQ: BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical development across multiple solid tumors. Data from Summit Therapeutics Inc . ...

11 months ago - Benzinga

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ: SMMT), noting the company’s initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed...

11 months ago - Benzinga